April 24th 2024
The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Vitamin C Boosts Effects of Chemotherapy and Lessens Toxicity
February 6th 2014A new study found that high concentrations of vitamin C increased the effectiveness of chemotherapy in an ovarian cancer mouse model. A high-dose delivery of the vitamin also resulted in lesser toxicity from chemotherapy in cancer patients.
ACR Appropriateness Criteria® Management of Vaginal Cancer
This article represents the consensus opinion of an expert panel and may be used to inform clinical recommendations in vaginal cancer management.
The Value of Pelvic Radiation Therapy After Hysterectomy for Early Endometrial Cancer
October 15th 2013In this review, the results and limitations of studies concerning adjuvant radiation therapy and chemotherapy for endometrial cancer will be discussed, focusing on evidence that can help to guide treatment decisions.
Pelvic Radiation Therapy for Early Endometrial Cancer: Careful Selection Is Key
October 15th 2013Future directions, including nomograms, multi-modality approaches, and more individualized patient care based on genomic profiles, may help to tailor each endometrial cancer patient’s therapy to her individual risk.